Biora Therapeutics (STU:4ZU0) ROCE % : 0.00% (As of Mar. 2024)

View and export this data going back to 2020. Start your Free Trial

What is Biora Therapeutics ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Biora Therapeutics's annualized ROCE % for the quarter that ended in Mar. 2024 was 0.00%.

Biora Therapeutics ROCE % Historical Data

The historical data trend for Biora Therapeutics's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biora Therapeutics ROCE % Chart

Biora Therapeutics Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

ROCE %

Get a 7-Day Free Trial

-721.60

-258.41

-269.53

-102.71

Biora Therapeutics Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
ROCE %	Get a 7-Day Free Trial															-201.16	-298.27	-	-	-

Biora Therapeutics ROCE % Calculation

Biora Therapeutics's annualized ROCE % for the fiscal year that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	-105.096	/	( ( (50.528 - 22)	+	(28.624 - 57.745) )	/ 2 )
	=	-105.096	/	( (28.528	+	-29.121)	/ 2 )
	=	-105.096	/	-0.2965
	=	35,445.53 %

Biora Therapeutics's ROCE % of for the quarter that ended in Mar. 2024 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Mar. 2024 )		(Q: Dec. 2023 )		(Q: Mar. 2024 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Mar. 2024 )		(Q: Dec. 2023 )		(Q: Mar. 2024 )
	=	-5.092	/	( ( (28.624 - 57.745)	+	(21.151 - 47.016) )	/ 2 )
	=	-5.092	/	( ( -29.121	+	-25.865 )	/ 2 )
	=	-5.092	/	-27.493
	=	0 %

(1) Note: The EBIT data used here is four times the quarterly (Mar. 2024) EBIT data.

Biora Therapeutics (STU:4ZU0) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Biora Therapeutics ROCE % Related Terms

Thank you for viewing the detailed overview of Biora Therapeutics's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Biora Therapeutics (STU:4ZU0) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Biora Therapeutics Inc (STU:4ZU0) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

BIOR:USA

Address

4330 La Jolla Village Drive, Suite 300, San Diego, CA, USA, 92122

Website

https://www.bioratherapeutics.com

Biora Therapeutics Inc is a biotechnology company engaged in developing oral biotherapeutics. Its drug-device combinations could enable new treatment approaches in the delivery of therapeutics in two main areas: Targeted delivery of therapeutics to the site of disease in the gastrointestinal ("GI") tract, which is designed to improve outcomes for patients with Inflammatory Bowel Disease (IBD); and Systemic delivery of biotherapeutics, which are designed to replace injection with needle-free, oral delivery technology. Geographically, it operates only in the United States.

Biora Therapeutics (STU:4ZU0) Headlines

No Headlines